US declaration on UN reform is not organization’s document - LavrovRussian Politics & Diplomacy September 24, 13:34
US not to strike on DPRK as it is aware Pyongyang has nuclear weapon - LavrovRussian Politics & Diplomacy September 24, 13:32
US forces assist Syrian opposition force in crossing IS positionsRussian Politics & Diplomacy September 24, 12:55
Putin discusses Russia’s economy growth with ministersBusiness & Economy September 24, 2:38
Lavrov warns against partition of SyriaRussian Politics & Diplomacy September 23, 0:00
Lavrov calls to coordinate Russian, US military action in SyriaRussian Politics & Diplomacy September 22, 21:05
Lavrov blames Obama administration for souring Russia-US tiesRussian Politics & Diplomacy September 22, 20:41
Waging war on Korean Peninsula inadmissible, says LavrovRussian Politics & Diplomacy September 22, 20:36
Russian Northern Fleet completes drills in ArcticMilitary & Defense September 22, 18:01
UNITED NATIONS, November 14. /TASS/. If the tests of experimental vaccines against the Ebola virus are successful, they will be available next year, UN Secretary-General’s special envoy David Nabarro said on Thursday. According to him, there are two highly promising potential vaccines. Sierra Leone’s Permanent Representative to the United Nations Vandi Chidi Minah told reporters that he expected “good news” about the results of the tests by the end of the current year.
According to the World Health Organization (WHO), the number of fatalities of the fever epidemic outbreak in West Africa has exceeded 5,100 people and 14,100 people have been infected. The situation is the most serious in Guinea, Liberia and Sierra Leone.
A number of countries are actively developing the Ebola vaccine. The UK, Japan, Russia and China have made progress in this area. On Wednesday, the international humanitarian organization Doctors Without Borders announced it would hold in December the vaccine testing in three medical centres in West Africa. Russia and China this week has allocated tens of millions of dollars for the development of the antiviral drugs.